MAPK15通过抑制JNK-JUN通路的氧化应激依赖激活来阻止IFNB1的表达
Monia Taranta1, Sara Panepinto2, Federico Galvagni3
1Istituto di Fisiologia Clinica (IFC), Consiglio Nazionale delle Ricerche (CNR), 53100 Siena, Italy.
International journal of molecular sciences
|June 13, 2025
概括
线素激活蛋白激酶15 (MAPK15) 下调通过诱导氧化应激和激活JUN.15来增强干扰素β (IFNB1) 表达. 这表明MAPK15是IFNB1的关键调节者,为炎症性疾病提供治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
背景情况:
- I型干扰素,包括贝塔干扰素 (IFNB1),对免疫反应至关重要.
- IFNB1的失调与各种疾病有关,因此需要研究其表达控制.
- 了解IFNB1调节的分子机制对于开发向疗法至关重要.
研究的目的:
- 为了确定干扰素β (IFNB1) 基因表达的新型调节剂.
- 阐明基激活蛋白激酶15 (MAPK15) 影响IFNB1.1. 的分子机制.
- 探索针对MAPK15在炎症条件下进行治疗干预的潜力.
主要方法:
- 路西法雷斯记者测量以评估主办方的活动.
- 基因表达分析 (例如,qPCR) 以量化mRNA水平.
- 酶相关免疫吸收试验 (ELISA) 用于测量蛋白质分泌.
- 对c-Jun N-终端激酶 (JNKs) 的药理抑制.
- 用N-乙半氨酸乙烯 (NACET) 治疗,以调查氧化应激的参与.
主要成果:
- 低调MAPK15显著增强了IFNB1和干扰素刺激基因表达.
- MAPK15下调导致IFNB1分泌量增加.
- 从机制上讲,MAPK15下调诱导了JUN激活,这取决于JNK信号传递.
- 由MAPK15下调引发的氧化应激被确定为JUN激活和随后的IFNB1表达的原因.
结论:
- 线素激活蛋白激酶15 (MAPK15) 是一种新型的干扰素β (IFNB1) 表达的负调节剂.
- 该机制涉及MAPK15诱导的氧化应激,导致JUN激活和IFNB1转录的增加.
- 向MAPK15为管理慢性炎症疾病中的免疫失调提供了潜在的治疗策略.
相关概念视频
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
cAMP-dependent Protein Kinase Pathways
6.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


